# Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients

> **NCT01916200** · PHASE4 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** Paroxetine CR

## Key facts

- **NCT ID:** NCT01916200
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was Cancelled Before Active
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916200, "Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01916200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*